Please try another search
Clover Biopharmaceuticals, Ltd., a biotechnology company, engages in the research, development, and commercialization of vaccines and biologic therapeutic candidates. The company develops SCB-2019 (CpG 1018/Alum), an adjuvanted protein-based COVID-19 vaccine candidate; AdimFlu-S (QIS), a quadrivalent vaccine for the treatment of influenza; SCB-2020S (CAS-1) and Multivalent SARS-CoV-2, a COVID-19 vaccine candidate; SCB-313, a trimeric fusion protein for the treatment of malignant ascites, malignant pleural effusions, and peritoneal carcinomatosis to address the global unmet medical need of intracavitary malignancies; SCB-219M, a human thrombopoietin receptor agonist (TPO-RA), which is in Phase 1 trial for the treatment of chemotherapy-induced thrombocytopenia; and SCB-1001, a rabies vaccine candidate. It develops its vaccines through Trimer-Tag technology platform. Clover Biopharmaceuticals, Ltd. was founded in 2007 and is headquartered in Shanghai, China.
Name | Age | Since | Title |
---|---|---|---|
Ralf Leo Clemens | 70 | 2022 | Non-Executive Director |
Xiaodong Wang | 60 | 2021 | Non-Executive Director |
Xiaobin Wu | 61 | 2021 | Independent Non-executive Director |
Joshua G. Liang | 30 | 2020 | CEO & Executive Director |
Peng Liang | 62 | 2018 | Founder, Chief Scientific Officer & Chairman of the Board |
Thomas Edward Leggett | 46 | 2021 | Independent Non-Executive Director |
Xiang Liao | 57 | 2021 | Independent Non-Executive Director |
Donna Marie Ambrosino | 71 | 2022 | Non-Executive Director |
Jeffrey S. Farrow | 61 | 2021 | Independent Non-Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review